


This listing of claims will replace all prior versions, and listings of claims in the application:

1. (Previously presented) A compound selected from the group consisting of formula (I) and formula (II):




A is thienyl optionally substituted with one, two or three substituents independently selected from the group consisting of lower alkoxy, lower alkyl, loweralkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide;

W is 1,4-phenylene optionally substituted with one, two or three substituents independently selected from the group consisting of lower alkoxy, lower alkyl, lower alkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide;

E is selected from the group consisting of H, -C₁-C₈ alkyl, polyhaloalkyl, -C₃₋₈-cycloalkyl, aryl optionally substituted with one, two or three substituents independently selected from the group consisting of lower alkoxy, lower alkyl, lower alkylamino, hydroxy, halogen, cyano, hydroxyl, mercapto, nitro, thioalkoxy, carboxaldehyde, carboxyl, carboalkoxy and carboxamide;

Dis



wherein:

n is an integer from 0-4,

X is in each case a member independently selected from the group consisting of:

halogen, polyhaloalkyl, $-OR^3$, $-SR^3$, $-CN$, $-NO_2$, $-SO_2R^3$, $-C_{1-10}$ -alkyl, $-C_{3-8}$ -cycloalkyl, aryl, aryl-substituted by 1-4 R^3 groups, amino, amino- C_{1-8} -alkyl, C_{1-3} -acylamino, C_{1-3} -acylamino- C_{1-8} -alkyl, C_{1-6} -alkylamino, C_{1-6} -alkylamino C_{1-8} alkyl, C_{1-6} dialkylamino, C_{1-6} dialkylamino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-3} -alkoxycarbonyl, C_{1-3} -alkoxycarbonyl- C_{1-6} -alkyl, carboxy C_{1-6} alkyloxy, hydroxy, hydroxy C_{1-6} alkyl, and a 5 to 10 membered fused or non-fused aromatic or nonaromatic heterocyclic ring system, having 1 to 4 heteroatoms independently selected from N, O, and S, with the proviso that the carbon and nitrogen atoms, when present in the heterocyclic ring system, are unsubstituted, mono- or di-substituted independently with 0-2 R^4 groups,

wherein R^3 and R^4 are each independently selected from the group consisting of:

hydrogen, halogen, $-CN$, $-NO_2$, $-C_{1-10}$ alkyl, C_{3-8} -cycloalkyl, aryl, amino, amino- C_{1-8} -alkyl, C_{1-3} -acylamino, C_{1-3} -acylamino- C_{1-8} -alkyl, C_{1-6} -alkylamino, C_{1-6} -alkylamino C_{1-8} alkyl, C_{1-6} dialkylamino, C_{1-6} dialkylannino C_{1-8} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxy - C_{1-6} -alkyl, carboxy- C_{1-6} -alkyl, C_{1-3} -alkoxycarbonyl, C_{1-3} -alkoxycarbonyl- C_{1-6} -alkyl, carboxy- C_{1-6} -alkyloxy, hydroxy, hydroxy- C_{1-6} -alkyl, -thio and thio- C_{1-6} -alkyl;

Y is selected from the group consisting of O, S, $N-OR^5$, and NR^5 ,

wherein R^5 is selected from the group consisting of:

H, C_{1-10} alkyl, C_{3-8} -cycloalkyl, and CN;

or pharmaceutically acceptable salts thereof.

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Previously presented) A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. (Canceled) A pharmaceutical composition of claim 7, wherein said therapeutically effective amount is an amount effective to inhibit platelet aggregation in the mammal.

9. (Canceled) A pharmaceutical composition of claim 8, wherein said platelet aggregation is platelet ADP-dependent aggregation.

10. (Previously presented) A pharmaceutical composition of claim 9, wherein said mammal is a human.

11. (Canceled) A pharmaceutical composition of claim 7, wherein said compound is an effective inhibitor of [³H2]-MeS-ADP binding to platelet ADP receptors.

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)


17. (Previously presented) A method for preventing or treating thrombosis in a mammal comprising the step of administering to a mammal a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

18. (Original) A method of claim 17, wherein said mammal is a human.

19. (Previously presented) A method of claim 17, wherein said mammal is prone to or suffers from a cardiovascular disease selected from at least one of the group consisting of acute myocardial infarction, unstable angina, chronic stable angina, transient ischemic attacks, strokes, peripheral vascular disease, preeclampsia/eclampsia, deep venous thrombosis, embolism, disseminated intravascular coagulation and thrombotic cytopenic purpura, thrombotic and restenotic complications following invasive procedures resulting from angioplasty, carotid endarterectomy, post CABG (coronary artery bypass graft) surgery, vascular gram surgery, stent placements and insertion of endovascular devices and prostheses.

20. (Canceled).

21. (Previously presented). A compound of claim 1 having the following formula:




wherein:

n is an integer from 0-4;


X is selected from the group consisting of 3-Br, 3-Cl, 4-OMe, 3-SO₂Me, 3-N(Me)₂, and 3,4-dimethyl;

W is selected from the group consisting of:




Y is selected from the group consisting of: O, S, N-C≡N, NH and N-OH; and

A is selected from the group consisting of:




22. (Previously presented). A compound of claim 1, having the following formula:



wherein:


Y is selected from the group consisting of: O, N-C \equiv N, NH and N-OH; and

A is selected from the group consisting of:



23. (Previously presented). A compound of claim 1, wherein A is thienyl.
24. (Previously presented). A compound of claim 1, wherein Y is O.
25. (Previously presented). A compound of claim 1, wherein E is hydrogen.
26. (Previously presented). A compound of claim 1, selected from the group

consisting of



27. (Previously presented). A compound of claim 1, having the formula:

